Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O43320
UPID:
FGF16_HUMAN
Alternative names:
-
Alternative UPACC:
O43320
Background:
Fibroblast growth factor 16 (FGF16) is a member of the fibroblast growth factor family, known for its pivotal role in regulating embryonic development, cell proliferation, and differentiation. This protein is essential for normal heart development and cardiomyocyte proliferation, highlighting its significance in early human development.
Therapeutic significance:
The association of FGF16 with Metacarpal 4-5 fusion, a rare congenital hand malformation, underscores its clinical relevance. Understanding the role of Fibroblast growth factor 16 could open doors to potential therapeutic strategies for congenital malformations and heart development anomalies.